YonFlow®: China’s First Fully Retractable Flow Diverter for Cerebral Aneurysm

On April 9, 2025, China’s National Medical Products Administration (NMPA) approved the market launch of the YonFlow® Flow Diverter, developed by NowYon Medical, a significant regulatory milestone, underscoring its unique retractable design and its clinically validated performance as a treatment for cerebral aneurysms.

The device is the first fully retractable flow diverter to be approved in China and is indicated for the treatment of unruptured saccular wide-neck or fusiform aneurysms in the internal carotid and vertebral arteries (parent vessel diameter: 2.0–6.0 mm).

Key Technical Features: The device’s principal innovation is its 100% retractable design. This feature allows for complete detachment and deployment, followed by retraction into the delivery system for repositioning. This capability is designed to enhance procedural fault tolerance and reduce complication risks associated with misplacement.

Further design and material innovations include:

• Balling Technology: Spheroidized distal ends are utilized to minimize delivery resistance and endothelial damage, thereby mitigating intraoperative thrombotic risks.
• Cobalt-Chromium Alloy: This material provides robust radial strength and optimal vessel-wall apposition, preventing device migration or collapse.
• Delivery System: The system is compatible with 0.021-inch microcatheters, and its optimized flexibility facilitates access to tortuous distal vasculature.

Disclaimer: The information on this platform is for informational purposes only and is based on publicly available sources, such as official press releases and regulatory databases. While we strive for accuracy, details may vary from the manufacturer’s official statements, particularly if they have been translated. We encourage readers to consult the manufacturer’s official website and communications for the most current and accurate information. This report is not a substitute for professional medical advice, diagnosis, or treatment and does not constitute an endorsement of any product or company. We do not accept responsibility for any errors, omissions, or actions taken based on the information provided.